SURE SWITZERLAND: A Multi-centre, Prospective, Non-interventional Study Investigating the Effectiveness of Once-weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SURE SWITZERLAND
- Sponsors Novo Nordisk
- 06 Oct 2023 Results of pooled post hoc analysis from SURE programme: Canada, Denmark/Sweden, France, Germany, Italy, the Netherlands, Switzerland, Spain and the UK psafety of once-weekly (OW) semaglutide prescribed to adults with type 2 diabetes (T2D) in routine clinical practice presented at the 59th Annual Meeting of the European Association for the Study of Diabetes.
- 16 Jan 2020 Status changed from active, no longer recruiting to completed.
- 09 Dec 2019 Planned primary completion date changed from 23 Dec 2019 to 29 Dec 2019.